BioCentury
ARTICLE | Clinical News

AG013: Phase Ib started

August 24, 2009 7:00 AM UTC

ActoGeniX began a single-blind, placebo-controlled, dose-escalation, U.S. Phase Ib trial to evaluate topical AG013 given 1, 3 or 6 times daily in 21 patients. ...